Back to search

Article

Finerenone ameliorates diabetic renal fibrosis via KRAS/FOXM1/SEMA3C signaling pathway in mesangial cells

2025-12-11

Abstract excerpt

<h4>Background: </h4> and Purpose: Hyperactivation of the mineralocorticoid receptor (MR) causes pro-inflammatory and pro-fibrotic actions, which are potential therapeutic targets of diabetic kidney disease (DKD). Finerenone (FIN), a novel non-steroidal mineralocorticoid receptor antagonist, attenuates vascular endothelial cell fibrosis in diabetic kidneys, but the precise mechanism remains unclear. Present study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d3bea3ef-cfb8-5ad4-ad8e-94e1069163f9
DOI
10.22541/au.176545938.83190905/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Finerenone ameliorates diabetic renal fibrosis via KRAS/FOXM1/SEMA3C signaling pathway in mesangial cellsDOI 10.22541/au.176545938.83190905/v1
Select a neighboring publication to make it the new centre.